This HTML5 document contains 168 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/chebi/
n25http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n31http://linked.opendata.cz/resource/drugbank/mixture/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/pharmgkb/
n24http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/bindingdb/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n30http://linked.opendata.cz/resource/drugbank/patent/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/pubchem-substance/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n32http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00975/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00975
rdf:type
n3:Drug
n3:description
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
n3:dosage
n7:271B4767-363D-11E5-9242-09173F13E4C5 n7:271B4768-363D-11E5-9242-09173F13E4C5 n7:271B475E-363D-11E5-9242-09173F13E4C5 n7:271B4763-363D-11E5-9242-09173F13E4C5 n7:271B4764-363D-11E5-9242-09173F13E4C5 n7:271B4765-363D-11E5-9242-09173F13E4C5 n7:271B4769-363D-11E5-9242-09173F13E4C5 n7:271B475F-363D-11E5-9242-09173F13E4C5 n7:271B4760-363D-11E5-9242-09173F13E4C5 n7:271B4761-363D-11E5-9242-09173F13E4C5 n7:271B4762-363D-11E5-9242-09173F13E4C5 n7:271B4766-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8981292
n3:group
approved
n3:halfLife
40 minutes
n3:indication
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
n3:manufacturer
n4:271B474C-363D-11E5-9242-09173F13E4C5 n4:271B4744-363D-11E5-9242-09173F13E4C5 n4:271B4745-363D-11E5-9242-09173F13E4C5 n4:271B4742-363D-11E5-9242-09173F13E4C5 n4:271B4743-363D-11E5-9242-09173F13E4C5 n4:271B4748-363D-11E5-9242-09173F13E4C5 n4:271B4749-363D-11E5-9242-09173F13E4C5 n4:271B4746-363D-11E5-9242-09173F13E4C5 n4:271B4747-363D-11E5-9242-09173F13E4C5 n4:271B474A-363D-11E5-9242-09173F13E4C5 n4:271B474B-363D-11E5-9242-09173F13E4C5 n4:271B474F-363D-11E5-9242-09173F13E4C5 n4:271B474D-363D-11E5-9242-09173F13E4C5 n4:271B474E-363D-11E5-9242-09173F13E4C5 n4:271B4740-363D-11E5-9242-09173F13E4C5 n4:271B4741-363D-11E5-9242-09173F13E4C5 n4:271B473E-363D-11E5-9242-09173F13E4C5 n4:271B473F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00975 n24:DB00975
dcterms:title
Dipyridamole
adms:identifier
n15:4653 n16:2997 n17:23620 n18:D00302 n19:55390-555-10 n20:DB00975 n21:46506292 n22:PA449367 n23:3108 n26:Dipyridamole
n3:mechanismOfAction
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
n3:packager
n4:271B4720-363D-11E5-9242-09173F13E4C5 n4:271B4721-363D-11E5-9242-09173F13E4C5 n4:271B471E-363D-11E5-9242-09173F13E4C5 n4:271B471F-363D-11E5-9242-09173F13E4C5 n4:271B471C-363D-11E5-9242-09173F13E4C5 n4:271B471D-363D-11E5-9242-09173F13E4C5 n4:271B4724-363D-11E5-9242-09173F13E4C5 n4:271B4722-363D-11E5-9242-09173F13E4C5 n4:271B4723-363D-11E5-9242-09173F13E4C5 n4:271B471B-363D-11E5-9242-09173F13E4C5 n4:271B472C-363D-11E5-9242-09173F13E4C5 n4:271B473C-363D-11E5-9242-09173F13E4C5 n4:271B473D-363D-11E5-9242-09173F13E4C5 n4:271B473A-363D-11E5-9242-09173F13E4C5 n4:271B473B-363D-11E5-9242-09173F13E4C5 n4:271B4738-363D-11E5-9242-09173F13E4C5 n4:271B4739-363D-11E5-9242-09173F13E4C5 n4:271B4736-363D-11E5-9242-09173F13E4C5 n4:271B4737-363D-11E5-9242-09173F13E4C5 n4:271B4734-363D-11E5-9242-09173F13E4C5 n4:271B4735-363D-11E5-9242-09173F13E4C5 n4:271B4732-363D-11E5-9242-09173F13E4C5 n4:271B4733-363D-11E5-9242-09173F13E4C5 n4:271B4730-363D-11E5-9242-09173F13E4C5 n4:271B4731-363D-11E5-9242-09173F13E4C5 n4:271B472E-363D-11E5-9242-09173F13E4C5 n4:271B472F-363D-11E5-9242-09173F13E4C5 n4:271B472B-363D-11E5-9242-09173F13E4C5 n4:271B472D-363D-11E5-9242-09173F13E4C5 n4:271B4729-363D-11E5-9242-09173F13E4C5 n4:271B472A-363D-11E5-9242-09173F13E4C5 n4:271B4727-363D-11E5-9242-09173F13E4C5 n4:271B4728-363D-11E5-9242-09173F13E4C5 n4:271B4725-363D-11E5-9242-09173F13E4C5 n4:271B4726-363D-11E5-9242-09173F13E4C5 n4:271B4719-363D-11E5-9242-09173F13E4C5 n4:271B471A-363D-11E5-9242-09173F13E4C5 n4:271B4717-363D-11E5-9242-09173F13E4C5 n4:271B4718-363D-11E5-9242-09173F13E4C5 n4:271B4715-363D-11E5-9242-09173F13E4C5 n4:271B4716-363D-11E5-9242-09173F13E4C5 n4:271B4713-363D-11E5-9242-09173F13E4C5 n4:271B4714-363D-11E5-9242-09173F13E4C5 n4:271B4711-363D-11E5-9242-09173F13E4C5 n4:271B4712-363D-11E5-9242-09173F13E4C5 n4:271B470F-363D-11E5-9242-09173F13E4C5 n4:271B4710-363D-11E5-9242-09173F13E4C5
n3:patent
n30:6015577
n3:routeOfElimination
Dipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.
n3:synonym
Dypyridamol Cleridium 150 Dipyridamolum Dipyudamine Cardoxin Curantyl Persantin Dipyridamine Dipiridamol
n3:toxicity
Hypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD<sub>50</sub> in rats is greater than 6,000 mg/kg while in the dogs, the oral LD<sub>50</sub> is approximately 400 mg/kg. LD<sub>50</sub>=8.4g/kg (orally in rat)
n3:volumeOfDistribution
* 1 to 2.5 L/kg
n8:hasAHFSCode
n25:24-12-92
n3:foodInteraction
Take with food to reduce irritation. Coffee and tea can decrease the effect of dipyridamole.
n3:mixture
n31:271B470E-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
99%
n3:synthesisReference
Minutza Leibovici, Itamar Kanari, Michael Fox, "Dipyridamole extended-release formulations and process for preparing same." U.S. Patent US20070184110, issued August 09, 2007.
n12:hasConcept
n13:M0006533
foaf:page
n28:dipyridamole.html n32:dipyrid.htm
n3:IUPAC-Name
n5:271B476E-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4774-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4773-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4770-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4771-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4772-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4784-363D-11E5-9242-09173F13E4C5 n5:271B476C-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4786-363D-11E5-9242-09173F13E4C5 n5:271B476D-363D-11E5-9242-09173F13E4C5 n5:271B476A-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B476B-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:B01AC07
n3:H-Bond-Acceptor-Count
n5:271B477A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B477B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4775-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4776-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4778-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4777-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4779-363D-11E5-9242-09173F13E4C5
n3:absorption
70%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
58-32-2
n3:category
n3:clearance
* 2.3-3.5 mL/min/kg
n3:containedIn
n6:271B475D-363D-11E5-9242-09173F13E4C5 n6:271B4753-363D-11E5-9242-09173F13E4C5 n6:271B4754-363D-11E5-9242-09173F13E4C5 n6:271B475B-363D-11E5-9242-09173F13E4C5 n6:271B475C-363D-11E5-9242-09173F13E4C5 n6:271B4759-363D-11E5-9242-09173F13E4C5 n6:271B475A-363D-11E5-9242-09173F13E4C5 n6:271B4751-363D-11E5-9242-09173F13E4C5 n6:271B4752-363D-11E5-9242-09173F13E4C5 n6:271B4750-363D-11E5-9242-09173F13E4C5 n6:271B4757-363D-11E5-9242-09173F13E4C5 n6:271B4758-363D-11E5-9242-09173F13E4C5 n6:271B4755-363D-11E5-9242-09173F13E4C5 n6:271B4756-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4780-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4782-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4783-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4785-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B477F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B477E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4781-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B476F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B477C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B477D-363D-11E5-9242-09173F13E4C5